ATE275406T1 - Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden - Google Patents
Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosidenInfo
- Publication number
- ATE275406T1 ATE275406T1 AT01937785T AT01937785T ATE275406T1 AT E275406 T1 ATE275406 T1 AT E275406T1 AT 01937785 T AT01937785 T AT 01937785T AT 01937785 T AT01937785 T AT 01937785T AT E275406 T1 ATE275406 T1 AT E275406T1
- Authority
- AT
- Austria
- Prior art keywords
- deoxy
- beta
- nucleosids
- methods
- hepatitis virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20753800P | 2000-05-26 | 2000-05-26 | |
PCT/US2001/017301 WO2001091737A2 (en) | 2000-05-26 | 2001-05-29 | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275406T1 true ATE275406T1 (de) | 2004-09-15 |
Family
ID=22771005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01937785T ATE275406T1 (de) | 2000-05-26 | 2001-05-29 | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
Country Status (18)
Country | Link |
---|---|
US (1) | US6596700B2 (de) |
EP (1) | EP1292313B1 (de) |
JP (1) | JP2004513070A (de) |
KR (1) | KR100854398B1 (de) |
CN (1) | CN100490818C (de) |
AT (1) | ATE275406T1 (de) |
AU (3) | AU2001263484B2 (de) |
BR (1) | BR0111195A (de) |
CA (1) | CA2410488C (de) |
DE (1) | DE60105424T2 (de) |
EA (1) | EA005890B1 (de) |
ES (1) | ES2227203T3 (de) |
HK (1) | HK1050999A1 (de) |
IL (1) | IL153078A0 (de) |
MX (1) | MXPA02011641A (de) |
TR (1) | TR200402565T4 (de) |
WO (1) | WO2001091737A2 (de) |
ZA (2) | ZA200210100B (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
ES2255295T3 (es) * | 1998-08-10 | 2006-06-16 | Idenix (Cayman) Limited | 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b. |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
AU2001245575A1 (en) * | 2000-03-09 | 2001-09-17 | Videoshare, Inc. | Sharing a streaming video |
ES2319732T3 (es) | 2000-04-13 | 2009-05-12 | Pharmasset, Inc. | Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales. |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
EP1736478B1 (de) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren |
PT1411954E (pt) * | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
MXPA04012802A (es) * | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
AU2003247084B9 (en) * | 2002-06-28 | 2018-07-26 | Centre National De La Recherche Scientifique | Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
AU2003263412A1 (en) * | 2002-06-28 | 2004-01-19 | Centre National De La Recherche Scientifique (Cnrs) | 1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
BR0314259A (pt) * | 2002-09-13 | 2005-07-26 | Idenix Cayman Ltd | ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas |
PL212929B1 (pl) * | 2002-10-31 | 2012-12-31 | Metabasis Therapeutics Inc | Pochodna cytarabiny, jej zastosowania oraz kompozycja farmaceutyczna zawierajaca ta pochodna |
MXPA05005192A (es) * | 2002-11-15 | 2005-09-08 | Idenix Cayman Ltd | Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae. |
CN1303089C (zh) * | 2002-11-19 | 2007-03-07 | 天津药物研究院 | 阿德福韦酯结晶形态及其制备方法 |
CN1330373C (zh) * | 2002-12-02 | 2007-08-08 | 美德(江西)生物科技有限公司 | 含alfa-干扰素,阿地福韦和二脱氧氟硫代胞嘧啶的药物组合物 |
CA2509687C (en) * | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
KR101177590B1 (ko) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
AR054778A1 (es) | 2005-06-17 | 2007-07-18 | Novartis Ag | Uso de sangliferina en hcv |
ES2422290T3 (es) * | 2005-12-23 | 2013-09-10 | Idenix Pharmaceuticals Inc | Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
AU2009329867B2 (en) | 2008-12-23 | 2015-01-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
JP5932829B2 (ja) * | 2010-12-10 | 2016-06-08 | シグマファーム ラボラトリーズ エルエルシー | 経***性ヌクレオチドアナログ又は経***性ヌクレオチドアナログプロドラッグの高度に安定な組成物 |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP3027598B1 (de) * | 2013-07-31 | 2017-04-12 | Merck Patent GmbH | Oxochinazolinylbutanamidderivate |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
MX2017016425A (es) * | 2015-06-17 | 2018-12-11 | Univ Columbia | Terapia con desoxinucleosidos para enfermedades generadas por grupos de nucleotidos desequilibrados, inclusive sindromes de agotamiento del adn mitocondrial. |
EP3344642A1 (de) | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Antivirale tetrahydrofuranderivate |
CN108264524A (zh) * | 2016-12-31 | 2018-07-10 | 正大天晴药业集团股份有限公司 | 恩曲他滨膦酸酯化合物 |
RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
RU2662161C1 (ru) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита |
EP3737676B1 (de) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetalverbindungen und therapeutische verwendungen davon |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
EP4157272A1 (de) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Verfahren zur behandlung von remdesivir |
MX2022016405A (es) | 2020-06-24 | 2023-01-30 | Gilead Sciences Inc | Análogos de nucleósido de 1¿-ciano y usos de estos. |
EP4200301A1 (de) | 2020-08-24 | 2023-06-28 | Gilead Sciences, Inc. | Phospholipidverbindungen und verwendungen davon |
JP2023540225A (ja) | 2020-08-27 | 2023-09-22 | ギリアード サイエンシーズ, インコーポレイテッド | ウイルス感染症の治療のための化合物及び方法 |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
JP3693357B2 (ja) * | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
WO1996011204A1 (de) | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
ES2255295T3 (es) | 1998-08-10 | 2006-06-16 | Idenix (Cayman) Limited | 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b. |
-
2001
- 2001-05-29 EA EA200201263A patent/EA005890B1/ru not_active IP Right Cessation
- 2001-05-29 AU AU2001263484A patent/AU2001263484B2/en not_active Ceased
- 2001-05-29 WO PCT/US2001/017301 patent/WO2001091737A2/en active IP Right Grant
- 2001-05-29 KR KR1020027015985A patent/KR100854398B1/ko not_active IP Right Cessation
- 2001-05-29 AT AT01937785T patent/ATE275406T1/de not_active IP Right Cessation
- 2001-05-29 ES ES01937785T patent/ES2227203T3/es not_active Expired - Lifetime
- 2001-05-29 CA CA002410488A patent/CA2410488C/en not_active Expired - Fee Related
- 2001-05-29 IL IL15307801A patent/IL153078A0/xx not_active IP Right Cessation
- 2001-05-29 AU AU6348401A patent/AU6348401A/xx active Pending
- 2001-05-29 TR TR2004/02565T patent/TR200402565T4/xx unknown
- 2001-05-29 MX MXPA02011641A patent/MXPA02011641A/es active IP Right Grant
- 2001-05-29 US US09/867,110 patent/US6596700B2/en not_active Expired - Fee Related
- 2001-05-29 BR BR0111195-7A patent/BR0111195A/pt not_active Application Discontinuation
- 2001-05-29 DE DE60105424T patent/DE60105424T2/de not_active Expired - Fee Related
- 2001-05-29 JP JP2001587753A patent/JP2004513070A/ja active Pending
- 2001-05-29 CN CNB018134297A patent/CN100490818C/zh not_active Expired - Fee Related
- 2001-05-29 EP EP01937785A patent/EP1292313B1/de not_active Expired - Lifetime
-
2002
- 2002-12-12 ZA ZA200210100A patent/ZA200210100B/en unknown
-
2003
- 2003-04-22 HK HK03102836A patent/HK1050999A1/xx not_active IP Right Cessation
-
2004
- 2004-06-01 ZA ZA200404304A patent/ZA200404304B/xx unknown
-
2006
- 2006-12-21 AU AU2006252214A patent/AU2006252214A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA005890B1 (ru) | 2005-06-30 |
AU6348401A (en) | 2001-12-11 |
TR200402565T4 (tr) | 2004-12-21 |
DE60105424T2 (de) | 2005-09-22 |
IL153078A0 (en) | 2003-06-24 |
ZA200404304B (en) | 2005-03-30 |
CA2410488C (en) | 2009-10-27 |
ZA200210100B (en) | 2004-06-22 |
WO2001091737A3 (en) | 2002-05-30 |
KR20030031487A (ko) | 2003-04-21 |
EA200201263A1 (ru) | 2003-06-26 |
US20020035085A1 (en) | 2002-03-21 |
EP1292313B1 (de) | 2004-09-08 |
KR100854398B1 (ko) | 2008-08-26 |
AU2006252214A1 (en) | 2007-01-18 |
CN1444483A (zh) | 2003-09-24 |
JP2004513070A (ja) | 2004-04-30 |
CN100490818C (zh) | 2009-05-27 |
US6596700B2 (en) | 2003-07-22 |
MXPA02011641A (es) | 2004-07-30 |
HK1050999A1 (en) | 2003-07-18 |
AU2001263484B2 (en) | 2006-12-14 |
WO2001091737A2 (en) | 2001-12-06 |
ES2227203T3 (es) | 2005-04-01 |
DE60105424D1 (de) | 2004-10-14 |
BR0111195A (pt) | 2004-07-20 |
EP1292313A2 (de) | 2003-03-19 |
CA2410488A1 (en) | 2001-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE275406T1 (de) | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden | |
MY164523A (en) | Methods and compositions for treating hepatitis c virus | |
ATE326236T1 (de) | Hpv-e7 zur behandlung von menschlichem papillomavirus | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
EA200201262A1 (ru) | Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения | |
ID27787A (id) | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan | |
CO5050303A1 (es) | Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion | |
ATE339211T1 (de) | L-fmau zur behandlung von hepatitis-delta-virus- infizierung | |
ZA991029B (en) | Composition and methods for treatment of hiv infections. | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
DE69231465T2 (de) | Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten | |
ATE100318T1 (de) | Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren. | |
DE60108775T8 (de) | Methode zur behandlung von schlaganfall | |
WO2003093415A3 (en) | Methods useful in treatment and prevention of hiv infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |